Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycyrrhizin, ammoniated

Drug Profile

Glycyrrhizin, ammoniated

Alternative Names: Glycyron Tablets; Stronger Neo-Minophagen C

Latest Information Update: 20 Dec 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Minophagen
  • Developer Erasmus Medical Center; Minophagen; University of Texas System
  • Class Antiulcers; Antivirals; Triterpenes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C
  • Discontinued Influenza virus infections

Most Recent Events

  • 18 Dec 2007 Eisai enters into in-licensing agreement with Minophagen for Japan and other countries
  • 14 Nov 2007 Data presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2007) added to the adverse events and Viral Infections therapeutic trials sections
  • 19 Jun 2003 A preclinical study has been added to the Viral Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top